Analytical Laboratory Services Market by Public Health Organization, - by types of services (Stability, Raw Material, Physical Characterization, Method Validation, Microbial Testing, Environmental Monitoring, Bioanalytical Testing) - Forecast to 2021
The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 million by 2021, growing at a CAGR of around 10.5% during the forecast period. Growth in the market can be attributed to a number of factors such as the growing expenditure on drugs and medical devices by public health organizations, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical laboratory services. However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support.
The analytical laboratory services market, by public health organization in this report is segmented by service type. In 2015, the bioanalytical testing segment accounted for the largest share of the analytical laboratory services market, by public health organization. This growth can be attributed to factors such as the usage and development of a large number of macromolecules and biosimilars for various therapeutic areas and the growing biopharmaceutical industry across the globe. The batch release testing services segment has the second largest share during the forecast period. The growth can be attributed to the need for checking and validating the process for product development among pharmaceutical & biopharmaceutical companies and the increasing usage of dissolution test in the development and approval of generic solid oral dosage forms.
In 2015, North America accounted for the largest share in the global analytical laboratory services market, by public health organization, followed by Europe, Asia-Pacific, and the RoW. Growth in the North American region is largely driven by the high expenditure on quality testing, strong regulatory scenario, increasing number of clinical trials, and the well-established federal testing laboratories in the region. Asia-Pacific is expected to grow at a higher CAGR during the forecast period as compared to North America and Europe. This can be attributed to the fast-growing pharmaceutical industry in this region, increased government expenditure on healthcare, increasing number of highly competitive and extremely fragmented pharmaceutical companies, and increased spending by governments to set up new laboratories in Asian countries.
The major public health organizations, in analytical laboratory services market, include the Food and Drug Administration (U.S.), European Medicines Agency (U.K.), Federal Institute for Drugs and Medical Devices (Germany), Agence francaise de securite sanitaire des produits de sante (France), Agenzia Italiana del Farmaco (Italy), the Spanish Medicines and Health Products Agency (Spain), Central Drugs Standard Control Organization (India), China Food and Drug Administration, and Pharmaceuticals and Medical Devices Agency (Japan).
Research Coverage
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the public expenditure based on region, which in turn would help them better understand the analytical laboratory services market, by public health organization. This report gives insight upon the various types of analytical laboratory services.
The analytical laboratory services market, by public health organization in this report is segmented by service type. In 2015, the bioanalytical testing segment accounted for the largest share of the analytical laboratory services market, by public health organization. This growth can be attributed to factors such as the usage and development of a large number of macromolecules and biosimilars for various therapeutic areas and the growing biopharmaceutical industry across the globe. The batch release testing services segment has the second largest share during the forecast period. The growth can be attributed to the need for checking and validating the process for product development among pharmaceutical & biopharmaceutical companies and the increasing usage of dissolution test in the development and approval of generic solid oral dosage forms.
In 2015, North America accounted for the largest share in the global analytical laboratory services market, by public health organization, followed by Europe, Asia-Pacific, and the RoW. Growth in the North American region is largely driven by the high expenditure on quality testing, strong regulatory scenario, increasing number of clinical trials, and the well-established federal testing laboratories in the region. Asia-Pacific is expected to grow at a higher CAGR during the forecast period as compared to North America and Europe. This can be attributed to the fast-growing pharmaceutical industry in this region, increased government expenditure on healthcare, increasing number of highly competitive and extremely fragmented pharmaceutical companies, and increased spending by governments to set up new laboratories in Asian countries.
The major public health organizations, in analytical laboratory services market, include the Food and Drug Administration (U.S.), European Medicines Agency (U.K.), Federal Institute for Drugs and Medical Devices (Germany), Agence francaise de securite sanitaire des produits de sante (France), Agenzia Italiana del Farmaco (Italy), the Spanish Medicines and Health Products Agency (Spain), Central Drugs Standard Control Organization (India), China Food and Drug Administration, and Pharmaceuticals and Medical Devices Agency (Japan).
Research Coverage
- Detailed insights on all analytical laboratory services, based on service type (bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring). This can help market players to identify key regional public spenders, and high growth segments in the analytical laboratory services market, by public health organization.
- The report also provides information on key government agencies and their spend assessment. This can help the company to assess the regulatory compliance at global and regional levels in a better manner.
- Country-wise market size and forecast for all the types of services. Thus, not only the high growth spenders and service areas; the market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize global efforts in order to achieve substantial assistance from public health organizations in the coming years.
- It provides insights on key trends and challenges faced by the public health organizations on analytical laboratory services market.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the public expenditure based on region, which in turn would help them better understand the analytical laboratory services market, by public health organization. This report gives insight upon the various types of analytical laboratory services.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 SCOPE OF THE REPORT
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of Primary Interviews
2.1.2.2 Key Industry Insights
2.1.3 MARKET SIZE ESTIMATION
3 EXECUTIVE SUMMARY
3.1 HEALTHCARE ANALYTICAL TESTING SERVICES: OVERVIEW
3.2 OUTSOURCED HEALTHCARE ANALYTICAL TESTING SERVICES
3.3 PUBLIC ORGANIZATION SPENDING ASSESSMENT FOR HEALTHCARE ANALYTICAL TESTING SERVICES
4 SPENDING ASSESSMENT OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS
4.2.1 GROWING EXPENDITURE ON DRUGS AND MEDICAL DEVICES BY PUBLIC ORGANIZATIONS
4.2.2 GOVERNMENT INITIATIVES TO STRENGTHEN ANALYTICAL TESTING CAPABILITIES
4.2.3 INCREASING NUMBER OF DRUG APPROVALS AND CLINICAL TRIALS
4.2.4 RISING DEMAND FOR SPECIALIZED ANALYTICAL TESTING SERVICES
4.3 CHALLENGES
4.3.1 COMPLEX AND INNOVATIVE PHARMACEUTICAL PRODUCTS REQUIRING A DISTINCTIVE ANALYTICAL TESTING APPROACH
4.4 CONCLUSION
5 PUBLIC ORGANIZATION SPEND ASSESSMENT FOR HEALTHCARE ANALYTICAL TESTING SERVICES: TYPES OF SERVICES
5.1 INTRODUCTION
5.2 BIOANALYTICAL TESTING
5.3 BATCH RELEASE TESTING
5.4 STABILITY TESTING
5.5 RAW MATERIAL TESTING
5.6 PHYSICAL CHARACTERIZATION
5.7 METHOD VALIDATION
5.8 MICROBIAL TESTING
5.9 ENVIRONMENTAL MONITORING
6 GEOGRAPHIC ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.2.1 U.S.
6.2.2 CANADA
6.3 EUROPE
6.3.1 GERMANY
6.3.2 U.K.
6.3.3 FRANCE
6.3.4 ITALY
6.3.5 SPAIN
6.3.6 REST OF EUROPE
6.4 ASIA-PACIFIC (APAC)
6.4.1 CHINA
6.4.2 JAPAN
6.4.3 INDIA
6.4.4 REST OF APAC
6.5 REST OF THE WORLD (ROW)
6.5.1 LATIN AMERICA
6.5.2 MIDDLE EAST AND AFRICA
7 APPENDIX
7.1 INSIGHTS OF KEY EXPERTS
7.2 RECENT DEVELOPMENTS
7.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
7.4 RELATED REPORTS
7.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 SCOPE OF THE REPORT
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of Primary Interviews
2.1.2.2 Key Industry Insights
2.1.3 MARKET SIZE ESTIMATION
3 EXECUTIVE SUMMARY
3.1 HEALTHCARE ANALYTICAL TESTING SERVICES: OVERVIEW
3.2 OUTSOURCED HEALTHCARE ANALYTICAL TESTING SERVICES
3.3 PUBLIC ORGANIZATION SPENDING ASSESSMENT FOR HEALTHCARE ANALYTICAL TESTING SERVICES
4 SPENDING ASSESSMENT OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS
4.2.1 GROWING EXPENDITURE ON DRUGS AND MEDICAL DEVICES BY PUBLIC ORGANIZATIONS
4.2.2 GOVERNMENT INITIATIVES TO STRENGTHEN ANALYTICAL TESTING CAPABILITIES
4.2.3 INCREASING NUMBER OF DRUG APPROVALS AND CLINICAL TRIALS
4.2.4 RISING DEMAND FOR SPECIALIZED ANALYTICAL TESTING SERVICES
4.3 CHALLENGES
4.3.1 COMPLEX AND INNOVATIVE PHARMACEUTICAL PRODUCTS REQUIRING A DISTINCTIVE ANALYTICAL TESTING APPROACH
4.4 CONCLUSION
5 PUBLIC ORGANIZATION SPEND ASSESSMENT FOR HEALTHCARE ANALYTICAL TESTING SERVICES: TYPES OF SERVICES
5.1 INTRODUCTION
5.2 BIOANALYTICAL TESTING
5.3 BATCH RELEASE TESTING
5.4 STABILITY TESTING
5.5 RAW MATERIAL TESTING
5.6 PHYSICAL CHARACTERIZATION
5.7 METHOD VALIDATION
5.8 MICROBIAL TESTING
5.9 ENVIRONMENTAL MONITORING
6 GEOGRAPHIC ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.2.1 U.S.
6.2.2 CANADA
6.3 EUROPE
6.3.1 GERMANY
6.3.2 U.K.
6.3.3 FRANCE
6.3.4 ITALY
6.3.5 SPAIN
6.3.6 REST OF EUROPE
6.4 ASIA-PACIFIC (APAC)
6.4.1 CHINA
6.4.2 JAPAN
6.4.3 INDIA
6.4.4 REST OF APAC
6.5 REST OF THE WORLD (ROW)
6.5.1 LATIN AMERICA
6.5.2 MIDDLE EAST AND AFRICA
7 APPENDIX
7.1 INSIGHTS OF KEY EXPERTS
7.2 RECENT DEVELOPMENTS
7.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
7.4 RELATED REPORTS
7.5 AUTHOR DETAILS
LIST OF TABLES
Table 1 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY REGION (USD MILLION)
Table 2 FUNDING ON HUMAN DRUGS AND DEVICES BY FDA, 2013–2017 (USD MILLION)
Table 3 BUDGET EXPENDITURE ON EVALUATION OF MEDICINAL PRODUCTS BY EMA, 2013–2015 (USD MILLION)
Table 4 NUMBER OF CLINICAL TRIALS AUTHORIZED BY COMPETENT AUTHORITIES (2011–2014)
Table 5 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 6 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 7 GLOBAL SPENDING ON BIOANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 8 GLOBAL SPENDING ON BATCH RELEASE TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 9 GLOBAL SPENDING ON STABILITY TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 10 GLOBAL SPENDING ON RAW MATERIAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 11 GLOBAL SPENDING ON PHYSICAL CHARACTERIZATION SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 12 GLOBAL SPENDING ON METHOD VALIDATION SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 13 GLOBAL SPENDING ON MICROBIAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 14 GLOBAL SPENDING ON ENVIRONMENTAL MONITORING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 15 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY REGION, 2014-2021 (USD MILLION)
Table 16 NORTH AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 17 NORTH AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 18 U.S.: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 19 CANADA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 20 EUROPE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 21 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 22 GERMANY: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 23 U.K.: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 24 FRANCE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 25 ITALY: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 26 SPAIN: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 27 ROE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 28 ASIA-PACIFIC: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 29 ASIA-PACIFIC: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 30 CHINA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 31 JAPAN: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 32 INDIA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 33 REST OF APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 34 ROW: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 35 ROW: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 36 LATIN AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 37 MIDDLE EAST AND AFRICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 1 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY REGION (USD MILLION)
Table 2 FUNDING ON HUMAN DRUGS AND DEVICES BY FDA, 2013–2017 (USD MILLION)
Table 3 BUDGET EXPENDITURE ON EVALUATION OF MEDICINAL PRODUCTS BY EMA, 2013–2015 (USD MILLION)
Table 4 NUMBER OF CLINICAL TRIALS AUTHORIZED BY COMPETENT AUTHORITIES (2011–2014)
Table 5 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 6 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 7 GLOBAL SPENDING ON BIOANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 8 GLOBAL SPENDING ON BATCH RELEASE TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 9 GLOBAL SPENDING ON STABILITY TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 10 GLOBAL SPENDING ON RAW MATERIAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 11 GLOBAL SPENDING ON PHYSICAL CHARACTERIZATION SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 12 GLOBAL SPENDING ON METHOD VALIDATION SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 13 GLOBAL SPENDING ON MICROBIAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 14 GLOBAL SPENDING ON ENVIRONMENTAL MONITORING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY/REGION, 2014–2021 (USD MILLION)
Table 15 SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY REGION, 2014-2021 (USD MILLION)
Table 16 NORTH AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 17 NORTH AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 18 U.S.: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 19 CANADA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 20 EUROPE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 21 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 22 GERMANY: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 23 U.K.: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 24 FRANCE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 25 ITALY: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 26 SPAIN: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 27 ROE: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 28 ASIA-PACIFIC: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 29 ASIA-PACIFIC: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 30 CHINA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 31 JAPAN: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 32 INDIA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 33 REST OF APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 34 ROW: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 35 ROW: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 36 LATIN AMERICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
Table 37 MIDDLE EAST AND AFRICA: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS, BY SERVICE TYPE, 2014–2021 (USD MILLION)
LIST OF FIGURES
Figure 1 SECONDARY RESEARCH APPROACH
Figure 2 PRIMARY RESEARCH APPROACH
Figure 3 MARKET SIZING APPROACH
Figure 4 MARKET SIZING METHODOLOGY
Figure 5 BIOANALYTICAL TESTING SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
Figure 6 GEOGRAPHIC SNAPSHOT: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS
Figure 7 FDA BUDGET ON MEDICAL DEVICES AND RADIOLOGICAL HEALTH, 2013–2017 (USD MILLION)
Figure 1 SECONDARY RESEARCH APPROACH
Figure 2 PRIMARY RESEARCH APPROACH
Figure 3 MARKET SIZING APPROACH
Figure 4 MARKET SIZING METHODOLOGY
Figure 5 BIOANALYTICAL TESTING SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
Figure 6 GEOGRAPHIC SNAPSHOT: SPENDING ON HEALTHCARE ANALYTICAL TESTING SERVICES BY PUBLIC ORGANIZATIONS
Figure 7 FDA BUDGET ON MEDICAL DEVICES AND RADIOLOGICAL HEALTH, 2013–2017 (USD MILLION)
